Alpha Wave Ventures, a global investment company, led a $30m investment in COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles. "As COUR set out to pursue its first institutional financing round in the Company's history, we were very fortunate to find a likeminded investor in Alpha Wave, which appreciates our innovation-driven culture and mission-critical approach to taking on big ideas in therapeutic areas where there are no or few therapies. The ability to secure a financing in these turbulent market conditions is a true testament to the tremendous capabilities of COUR's team, technology and results to date. With this important infusion of capital, we look forward to rapidly advancing our revolutionary drug candidates aimed to reprogram the immune system for people suffering from immune disorders," John J. Puisis, COUR CEO and Founder.